Is cagrilintide a GLP-1 drug?

No. It is an amylin analogue. Amylin is a separate hormone with its own receptor complex and its own satiety pathway.

Why can native amylin not be used?

It aggregates into amyloid fibrils. Clinical analogues substitute residues at the aggregation-prone positions to prevent it.

GLP-1 & Incretin Science

What Is Cagrilintide? The Amylin Half of CagriSema

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Cagrilintide is a long-acting analogue of amylin, the satiety hormone co-secreted with insulin. Engineered for once-weekly administration, it is the amylin component of CagriSema. Native human amylin cannot be used as a drug because it aggregates into amyloid fibrils.

Key facts

Class: Long-acting amylin receptor agonist
Developer: Novo Nordisk
Molecular weight: ~4,409 Da
Molecular formula: C194H312N54O59S2
PubChem CID: 171397054
Administration: Once weekly, subcutaneous
Combined with: Semaglutide, as CagriSema
Predecessor: Pramlintide (meal-time dosing)

The problem native amylin presents

Human amylin is a 37-residue hormone that aggregates readily into amyloid fibrils. That is not merely a formulation nuisance — it is the same process that deposits islet amyloid in type 2 diabetes. A drug that self-assembles into insoluble fibrils in the vial or at the injection site is not viable, which is why amylin analogues had to solve aggregation before they could solve anything else.

How the problem was first solved

Pramlintide, the first clinical amylin analogue, borrowed proline substitutions from rat amylin, which does not aggregate. Those substitutions disrupted the sequence's propensity to form the ordered structure amyloid requires. Pramlintide worked but had a short half-life and needed dosing with meals, which limited its practical use.

What cagrilintide changes

Cagrilintide is engineered for once-weekly administration, which brings amylin pharmacology into the same dosing rhythm as the modern GLP-1 analogues. That matters for combination: pairing a weekly GLP-1 agonist with a meal-time amylin analogue would be impractical, whereas two weekly components can be delivered as a single fixed-dose product.

Why pair it with semaglutide at all

Amylin and GLP-1 reduce food intake through largely separate routes — amylin principally via the area postrema, GLP-1 via hypothalamic and vagal pathways. Because the pathways do not fully overlap, their effects add rather than saturate. REDEFINE 1 tested exactly this, comparing the combination against each component alone, and the combination outperformed both.

The evidence behind the combination

REDEFINE 1, in adults with obesity and without diabetes, reported 22.7% mean reduction at 68 weeks among participants who adhered and 20.4% across all randomised, against 2.3% and 3.0% on placebo respectively. REDEFINE 2, in adults with type 2 diabetes, reported 15.7% at 68 weeks against 3.1% on placebo — a smaller figure, which is the expected pattern in diabetic populations across the entire class.

Status

Cagrilintide is investigational as a single agent. As part of CagriSema it has been filed with the FDA, with a decision expected in the fourth quarter of 2026. It holds no MHRA authorisation.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is cagrilintide a GLP-1 drug?: No. It is an amylin analogue. Amylin is a separate hormone with its own receptor complex and its own satiety pathway.
Why can native amylin not be used?: It aggregates into amyloid fibrils. Clinical analogues substitute residues at the aggregation-prone positions to prevent it.
How does it differ from pramlintide?: Pramlintide is short-acting and requires dosing with meals. Cagrilintide is engineered for once-weekly administration, which makes weekly combination products possible.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum